Clinical trial · Observational
Τreatment Standards and Outcomes of Patients With ER/PR Positive, HER2-negative Metastatic Breast Cancer
Non-Interventional, Multi-center Registry of Recording of Treatment Standards and Outcomes of Patients With ER/PR Positive, HER2-negative Metastatic Breast Cancer
NCT04247035CI-TRIAL-00049985MBCunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
• To capture the treatment patterns and clinical characteristics of patients with ER/PR positive, HER2-negative MBC in Greece
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Breast Cancer | Malignant Breast Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Evaluation of the outcome per treatment line
- timeFrame
- 5 years
- description
- To evaluate the outcome of patients per treatment line (objective response, progression free survival, time to disease progression per line of therapy), overall survival
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Women with histological confirmed ER/PR positive, HER2-negative MBC * Age \>18 years old * Patients initiating first or second line therapy for ER/PR positive, HER2-negative MBC * Adequate hematologic, renal and hepatic function * Signed informed consent (ICF) Exclusion Criteria: * Active malignancy other than MBC * Active infection
References
Publications (0)
Data not yet available
No reference posted for this study.